Dtsch Med Wochenschr 2011; 136(40): 2029-2032
DOI: 10.1055/s-0031-1286387
Pneumologie | Commentary
Pneumologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Pneumologische Onkologie

Thoracic oncologyL. H. Schmidt1 , M. Mohr1 , R. Wiewrodt1
  • 1Schwerpunkt Pneumologie, Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster
Further Information

Publication History

Publication Date:
28 September 2011 (online)

    Permissions and Reprints

Schlüsselwörter

Lungenkrebs - Früherkennung - EGFR-Mutationen

Keywords

lung cancer - early detection - EGFR mutations

Literatur

  • 1 Becker G, Hatami I, Xander C. et al . Palliative cancer care: an epidemiologic study.  J Clin Oncol. 2011;  29 646-650
    Google Scholar
  • 2 Cappuzzo F, Ciuleanu T, Stelmakh L. et al . Erlotinib as maintenance treatment in advanced non-small-cell lung cancer.  Lancet Oncol. 2010;  11 521-529
    Google Scholar
  • 3 Cataldo V D, Gibbons D L, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib.  N Engl J Med. 2011;  364 947-955
    Google Scholar
  • 4 Ciuleanu T, Brodowicz T, Zielinski C. et al . Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.  Lancet. 2009;  374 1432-1440
    Google Scholar
  • 5 Cohen M H, Johnson J R, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).  Oncologist. 2010;  15 1344-1351
    Google Scholar
  • 6 Davidoff A J, Tang M, Seal B, Edelman M J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.  J Clin Oncol. 2010;  28 2191-2197
    Google Scholar
  • 7 Fidias P M, Dakhil S R, Lyss A P. et al . Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.  J Clin Oncol. 2009;  27 591-598
    Google Scholar
  • 8 Goeckenjan G, Sitter H, Thomas M. et al . [Prevention, diagnosis, therapy, and follow-up of lung cancer].  Pneumologie. 2010;  64 Suppl 2 e1-164
    Google Scholar
  • 9 Goldstraw P, Crowley J, Chansky K. et al . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.  J Thorac Oncol. 2007;  2 706-714
    Google Scholar
  • 10 Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer.  J Clin Oncol. 2009;  27 4232-4235
    Google Scholar
  • 11 Jackman D, Pao W, Riely G J. et al . Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.  J Clin Oncol. 2010;  28 357-360
    Google Scholar
  • 12 Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics.  CA Cancer J Clin. 2011;  61 69-90
    Google Scholar
  • 13 Kris M G, Johnson B E, Kwiatkowski D J. et al . Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).  J Clin Oncol. 2011;  29 Suppl: abstr CRA7506
    Google Scholar
  • 14 Kwak E L, Bang Y J, Camidge D R. et al . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.  N Engl J Med. 2010;  363 1693-1703
    Google Scholar
  • 15 Maemondo M, Inoue A, Kobayashi K. et al . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.  N Engl J Med. 2010;  362 2380-2388
    Google Scholar
  • 16 Mitsudomi T, Morita S, Yatabe Y. et al . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405).  Lancet Oncol. 2010;  11 121-128
    Google Scholar
  • 17 Mok T S, Wu Y L, Thongprasert S. et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.  N Engl J Med. 2009;  361 947-957
    Google Scholar
  • 18 Pao W, Girard N. New driver mutations in non-small-cell lung cancer.  Lancet Oncol. 2011;  12 175-180
    Google Scholar
  • 19 Quoix E A, Oster J, Westeel V. et al . Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89.  J Clin Oncol. 2010;  28 Suppl 18s, abstr 2
    Google Scholar
  • 20 Sequist L V, Heist R S, Shaw A T. et al . SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.  J Clin Oncol. 2011;  29 Suppl abstr 7518
    Google Scholar
  • 21 Soon Y Y, Stockler M R, Askie L M, Boyer M J. Duration of chemotherapy for advanced non-small-cell lung cancer.  J Clin Oncol. 2009;  27 3277-3283
    Google Scholar
  • 22 Stinchcombe T E, Socinski M A. Maintenance therapy in advanced non-small cell lung cancer: current status and future implications.  J Thorac Oncol. 2011;  6 174-182
    Google Scholar
  • 23 Temel J S, Greer J A, Muzikansky. et al . Early palliative care for patients with metastatic non-small-cell lung cancer.  N Engl J Med. 2010;  363 733-742
    Google Scholar
  • 24 The National Lung Screening Trial Research Team . Reduced Lung-Cancer Mortality with low-dose computed tomographic screening.  N Engl J Med. 2011;  365 395-409
    Google Scholar
  • 25 Travis W D, Brambilla E, Noguchi M. et al . International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.  J Thorac Oncol. 2011;  6 244-285
    Google Scholar
  • 26 Vogelmeier C, Worth H, Pfeifer M. et al . [Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT].  Pneumologie. 2011;  65 5-6
    Google Scholar

Univ.-Prof. Dr. med. Rainer Wiewrodt

Klinik und Poliklinik für Innere Medizin A mit den Schwerpunkten Hämatologie, Onkologie und Pneumologie
Universitätsklinikum Münster

Albert-Schweitzer-Campus 1, Gebäude A1

48149 Münster

Phone: 0251/8344803

Fax: 0251/8344804

Email: rainer.wiewrodt@ukmuenster.de